A HIGHLY SENSITIVE QUANTITATIVE BIOASSAY FOR HUMAN INTERLEUKIN-11

被引:25
作者
LU, ZY
ZHANG, XG
GU, ZJ
YASUKAWA, K
AMIOT, M
ETRILLARD, M
BATAILLE, R
KLEIN, B
机构
[1] CNRS,INST MOLEC GENET,F-34033 MONTPELLIER,FRANCE
[2] SUZHOU MED COLL,SUZHOU 215007,PEOPLES R CHINA
[3] TOSOH CORP,BIOTECHNOL RES LAB,AYASE,KANAGAWA 252,JAPAN
[4] INST BIOL,ONCOGENESE LAB,F-44035 NANTES,FRANCE
关键词
IL-11; IL-6; CYTOKINE;
D O I
10.1016/0022-1759(94)90278-X
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Human interleukin-11 (IL-11) is a cytokine with a broad spectrum of activity, similar to interleukin-6 (IL-6). However, its role in human disease is poorly understood, partly because of a lack of sensitive bioassays. A subclone (B9-11) obtained from the B9 hybridoma (which responds poorly to human IL-11) enabled us to develop a highly sensitive bioassay for human IL-11. B9-11 cells responded only to human IL-11 and IL-6 and not to other human cytokines using the same gp130 transducer chain (ciliary neurotrophic factor, leukemia inhibitory factor and oncostatin M) or to other human interleukins (interleukin-1 to interleukin-13), human hematopoietic cytokines (granulocyte colony stimulating factor, granulocyte-macrophage colony stimulating factor, colony stimulating factor-1) and various other human cytokines (interferon-alpha, tumor necrosis factor-alpha, tumor necrosis factor-beta, fibroblast growth factor and nerve growth factor). In addition, these cytokines did not interfere with the IL-11 response of B9-11 cells. IL-11-induced proliferation of B9-11 cells was unaffected by anti-murine IL-6 receptor mAb but inhibited by anti-gp130 mAb. Half-maximal proliferation of B9-11 cells was obtained with 30 pg/ml of recombinant IL-11, a concentration 300-fold lower than IL-11 concentrations known to be active on human cells. Finally, culturing of B9-11 cells with an anti-IL-6 mAb enabled us to measure the natural IL-11 produced by various cell lines. Thus, B9-11 cells should be useful for studies of IL-11 involvement in various human diseases as well as for a better understanding of the mechanisms of action of this cytokine.
引用
收藏
页码:19 / 26
页数:8
相关论文
共 15 条
  • [1] ANDERSON KC, 1992, BLOOD, V80, P2797
  • [2] BAUMANN H, 1991, J BIOL CHEM, V266, P20424
  • [3] BURGER R, 1993, J IMMUNOL METHODS, V160, P277
  • [4] LEUKEMIA INHIBITORY FACTOR RECEPTOR IS STRUCTURALLY RELATED TO THE IL-6 SIGNAL TRANSDUCER, GP130
    GEARING, DP
    THUT, CJ
    VANDENBOS, T
    GIMPEL, SD
    DELANEY, PB
    KING, J
    PRICE, V
    COSMAN, D
    BECKMANN, MP
    [J]. EMBO JOURNAL, 1991, 10 (10) : 2839 - 2848
  • [5] FUNCTIONAL DISCRIMINATION BETWEEN INTERLEUKIN-6 AND INTERLEUKIN-1
    HELLE, M
    BOEIJE, L
    AARDEN, LA
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 1988, 18 (10) : 1535 - 1540
  • [6] BIOLOGICAL AND CLINICAL ASPECTS OF INTERLEUKIN-6
    HIRANO, T
    AKIRA, S
    TAGA, T
    KISHIMOTO, T
    [J]. IMMUNOLOGY TODAY, 1990, 11 (12): : 443 - 449
  • [7] CNTF AND LIF ACT ON NEURONAL CELLS VIA SHARED SIGNALING PATHWAYS THAT INVOLVE THE IL-6 SIGNAL TRANSDUCING RECEPTOR COMPONENT GP130
    IP, NY
    NYE, SH
    BOULTON, TG
    DAVIS, S
    TAGA, T
    LI, YP
    BIRREN, SJ
    YASUKAWA, K
    KISHIMOTO, T
    ANDERSON, DJ
    STAHL, N
    YANCOPOULOS, GD
    [J]. CELL, 1992, 69 (07) : 1121 - 1132
  • [8] MOLECULAR-CLONING OF A CDNA-ENCODING INTERLEUKIN-11, A STROMAL CELL-DERIVED LYMPHOPOIETIC AND HEMATOPOIETIC CYTOKINE
    PAUL, SR
    BENNETT, F
    CALVETTI, JA
    KELLEHER, K
    WOOD, CR
    OHARA, RM
    LEARY, AC
    SIBLEY, B
    CLARK, SC
    WILLIAMS, DA
    YANG, YC
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (19) : 7512 - 7516
  • [9] PAUL SR, 1991, BLOOD, V77, P1723
  • [10] PERSPECTIVES - INTERLEUKIN-6 - AN OSTEOTROPIC FACTOR
    ROODMAN, GD
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 1992, 7 (05) : 475 - 478